V. Molecular classification and risk stratification of myeloma

Hematological Oncology

Volumn 31, Issue SUPPL 2, 2013, Pages 38-41

  Bergsagel, P Leif ^a   Chesi, Marta ^a  

^a MAYO CLINIC   (United States)

Author keywords

Chromosome translocation; Multiple myeloma; Pathogenesis; Risk stratification

Indexed keywords

B RAF KINASE; CYCLIN D1; CYCLIN D2; CYCLIN D3; IMMUNOGLOBULIN HEAVY CHAIN; MYC PROTEIN; PROTEIN P53;

ARTICLE; CANCER RISK; CHROMOSOME 13; CHROMOSOME 17P; CHROMOSOME 1P; CHROMOSOME 1Q; CHROMOSOME DELETION; CHROMOSOME LOSS; CYCLIN D GENE; FGFR3 GENE; GENE; GENE EXPRESSION; GENE MUTATION; GENE TRANSLOCATION; MAF GENE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MYELOMA; ONCOGENE K RAS; ONCOGENE N RAS; PRIORITY JOURNAL; TRISOMY; TUMOR CLASSIFICATION; TUMOR GROWTH;

CYCLIN D; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; PROTO-ONCOGENE PROTEINS C-MAF; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; REPRESSOR PROTEINS; TRANSLOCATION, GENETIC; TRISOMY;

EID: 84879341699     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.2065     Document Type: Article

References (15)

1. Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. The Journal of Clinical Investigation 2012; 122: 3456-63.
2. Martinez-Garcia E, Popovic R, Min D-J, Sweet SMM, Thomas PM, Zamdborg L, et al. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood 2011; 117: 211-20.
3. Kuo AJ, Cheung P, Chen K, Zee BM, Kioi M, Lauring J, et al. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Molecular Cell 2011; 44: 609-20.
4. Pei H, Zhang L, Luo K, Qin Y, Chesi M, Fei F, et al. MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. Nature 2011; 470: 124-8.
5. Kumar S, Fonseca R, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood 2012; 119: 2100-5.
6. Chng WJ, Huang GF, Chung T-H, Ng SB, Gonzalez-Paz N, Troska-Price T, et al. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia 2011; 25: 1026-35.
7. Chesi M, Robbiani DF, Sebag M, Chng WJ, Affer M, Tiedemann R, et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 2008; 13: 167-80.
8. Chesi M, Matthews GM, Garbitt VM, Palmer SE, Shortt J, Lefebure M, et al. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood 2012; 120: 376-85.
9. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146: 904-17.
10. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471: 467-72.
11. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007; 12: 131-44.
12. Pichiorri F, Suh S-S, Rocci A, De Luca L, Taccioli C, Santhanam R, et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 2010; 18: 367-81.
13. Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, et al. Clonal competition with alternating dominance in multiple myeloma. Blood 2012; 120: 1067-76.
14. Bergsagel PL, Mateos MV, Gutierrez NC, Rajkumar SV, San Miguel JF. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood 2013; 121: 884-92.
15. Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clinic Proceedings. 2013;88: 360-76.